Recent research into retatrutide peptide reveal promising outlook for managing weight and type diabetes. The compound, a dual agonist of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, appears to offer improved weight reduction and glucose control versus existing medications. Additional clinical trials are necessary to ful